ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
|
|
- Ashlee Lindsey
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7: ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Serologic Markers Do Not Predict Histologic Severity or Response to Treatment in Patients With Autoimmune Hepatitis VAIBHAV MEHENDIRATTA,* PRADNYA MITROO, ALESSANDRO BOMBONATI, VICTOR J. NAVARRO, SIMONA ROSSI, RAPHAEL RUBIN, and STEVEN K. HERRINE *Department of Medicine, Division of Gastroenterology and Hepatology, and Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania See Lok AS et al on page 138 for companion article in the January 2009 issue of Gastroenterology. Background & Aims: Autoimmune hepatitis (AIH) is characterized by the presence of circulating autoantibodies, hypergammaglobulinemia, necroinflammatory histology, and a response to immunosuppressive drugs. The goal of this retrospective study was to determine whether the presence of antinuclear antibodies (ANAs) or anti smooth muscle antibodies (ASMAs) in patients with AIH correlated with clinical presentation, histologic findings, or response to immunosuppressive therapy. Methods: Fifty-two patients diagnosed with AIH, on the basis of the revised scoring system of International Autoimmune Hepatitis group, were reviewed. Data on age, gender, aminotransferase levels, autoantibody titers, treatment regimens, and response to treatment were recorded. Seropositivity was defined as ANA >1:40 or ASMA >1:40. Percutaneous liver biopsies obtained at the initial presentation were reviewed. Results: Forty-two patients with AIH (81%) were seropositive, and 10 (19%) were seronegative. Both groups were similar with respect to demographics, treatment regimens, and response to therapy. Histologic parameters were similar among the 2 groups, including portal and lobular inflammation, piecemeal necrosis, and centrilobular necrosis. There were no significant differences in aminotransferase levels at diagnosis or after treatment. Conclusions: The prevalence of ANAs or ASMAs did not correlate with the clinical or histologic severity of AIH at diagnosis. Furthermore, there was no correlation between antibody status and response to immunosuppressive therapy. Therefore, patients who meet the diagnosis of AIH on the basis of the revised scoring system of International Autoimmune Hepatitis Group should be given immunosuppressive therapy, regardless of antibody status. Autoimmune hepatitis (AIH) is a chronic hepatitis of unknown cause that occurs in children and adults of all ages. The disease is characterized by the presence of circulating autoantibodies, hypergammaglobulinemia, necroinflammatory histology, and response to immunosuppressive drugs (eg, prednisone and azathioprine). The diagnosis of AIH, which requires the presence of characteristic clinical features and the exclusion of other conditions that resemble AIH, has been codified and updated by the International Autoimmune Hepatitis Group (IAIHG). 1,2 Differences between a definite and probable diagnosis of AIH relate mainly to the degree of serum -globulin or immunoglobulin G elevation, levels of autoantibodies, and exposures to alcohol, medications, or infections that could cause liver injury. Histologic features of AIH variably include portal and lobular lymphoplasmacytic necroinflammatory infiltrates, piecemeal necrosis, and bridging necrosis. Severe cases are associated with the formation of liver cell rosettes and nodular regeneration. 2 These individual features (interface hepatitis, predominantly lymphoplasmacytic necroinflammatory infiltrate, and rosetting of liver cells) have been incorporated in the diagnostic scoring system of IAIHG and constitute 19% of the maximum score allowable for a definite diagnosis of AIH. 1 4 Absence of the above mentioned features and presence of biliary and other incompatible changes raise doubt about the diagnosis and reduce the score by 42%. Although it is reaffirmed that there are no morphologic findings characteristic of AIH, absence of compatible histologic features or presence of incompatible histologic features preclude a definite diagnosis of AIH, regardless of other supportive clinical findings. Antinuclear antibodies (ANAs) and anti smooth muscle antibodies (ASMAs) are the most common markers for type I AIH, but about 20% 30% of AIH patients present without significant titers ( 1:40) of these autoantibodies, whereas up to 20% have no detectable autoantibodies. 2,5 7 Although antibodies play a pivotal role in the initial diagnosis of AIH, they are neither pathogenic nor disease-specific. 8 Autoantibody titers at presentation correlate poorly with disease severity, degree of liver injury, and response to treatment. 8 Whether the absence of Abbreviations used in this paper: AIH, autoimmune hepatitis; ANA, antinuclear antibody; ASMA, anti smooth muscle antibody; ELISA, enzyme-linked immunosorbent assay; HEp-2, human epithelioid 2; IAIHG, International Autoimmune Hepatitis Group; IIF, indirect immunofluorescence; LKM, anti liver-kidney microsomes by the AGA Institute /09/$36.00 doi: /j.cgh
2 January 2009 SEROLOGY IN AUTOIMMUNE HEPATITIS 99 autoantibodies has a favorable prognosis on the degree of liver injury or response to immunosuppression is unclear. The goals of the present study were to calculate the prevalence of autoantibodies in patients diagnosed with AIH and to determine whether their presence correlates with clinical presentation, histologic findings, or response to immunosuppressive therapy. Materials and Methods Patient Selection Electronic billing records at our university hepatology practice were used to identify patients diagnosed with International Classification of Diseases, ninth revision code (Hepatitis, Autoimmune/Not otherwise specified) between 1999 and The revised scoring system of the IAIHG was used to identify patients who met the probable diagnosis of AIH by having a pretreatment score of more than 10. Patients were included in the study if they were treated with immunosuppressive therapy, were followed for 6 months after treatment initiation, and had liver biopsy slides available for review. Exclusion criteria included pretreatment aggregate score 10, pretreatment score 10 but insufficient available follow-up data, features of other liver diseases such as hemochromatosis, Wilson s disease, primary biliary cirrhosis, alcoholic hepatitis, or viral hepatitis, or absence of liver tissue specimens for review. Patients who were found to have antibodies against hepatotropic viruses were included if they were nonviremic and the clinical features of their liver disease were consistent with AIH. Data Collection Charts of patients who met inclusion criteria were retrospectively reviewed to record age, gender, serum aminotransferase levels, serum autoantibody levels, and treatment regimens. ALT and AST levels at diagnosis and then at 1 month, 6 months, and 1 year after treatment were collected. Treatment failure was defined as worsening clinical (development of jaundice, ascites, or hepatic encephalopathy) or laboratory (increase in serum aminotransferase levels by 67%) features despite compliance with therapy. Data collection methods were approved by the Institutional Review Board of Thomas Jefferson University. Autoantibody Testing The technique used to test for routine antibodies associated with AIH was indirect immunofluorescence (IIF). Slides prepared from human epithelioid 2 (HEp-2) cell lines as substrate were incubated with diluted serum, and the presence of ANAs was detected by fluorescent anti-ig antibody. Similarly, a mouse stomach-kidney substrate was used to test for ASMAs, and specific staining pattern was recognized with the addition of diluted sera. If staining pattern was suspicious for presence of anti liver-kidney microsome type-1 (anti-lkm-1) antibody, further testing with a liver-kidney-stomach substrate was used to confirm presence of the autoantibody. Seropositivity was defined as ANA 1:40 and/or ASMA 1:40. Histologic Evaluation Liver biopsy slides obtained before treatment initiation were reviewed. Sections were stained with hematoxylin-eosin and Masson trichrome. Two pathologists, who were blinded to clinical and serologic data, reviewed all slides. The degree of liver injury on histology was defined by 8 individual categories including plasma cells, portal inflammation, lobular inflammatory activity, piecemeal necrosis, centrilobular necrosis, bile duct proliferation, cholestasis, and pericholangitis. Each category was graded on a scale of 0 4. In addition, the stage of fibrosis was assessed on a scale of 0 6 (Figure 1). Statistical Analysis Comparison between means was performed by Student t test. The Mann-Whitney U test was used to evaluate the difference between means for non-normally distributed data. All statistical analyses were conducted with SAS statistical software (version 9.1; SAS Institute, Cary, NC), with P.05 considered to be statistically significant. Results Patient Population Two hundred patients were identified by using International Classification of Diseases, ninth revision code 573.3, of whom 87 met the diagnosis of AIH according to revised scoring system of the IAIHG. Twelve patients were excluded as a result of insufficient clinical information, 17 were excluded as a result of absence of liver biopsy specimens for review, and 6 were excluded as a result of concomitant infection with hepatotropic viruses and presence of viremia. Two patients (1 seropositive and 1 seronegative) with positive anti-hcv antibody and negative HCV polymerase chain reaction RNA were included in the study. Results from 52 patients who met all inclusion criteria are discussed below. Demographics The mean age of patients was years, with 41 (79%) being female. The patients with autoantibodies were similar to the patients without autoantibodies with respect to age and gender (Table 1). Serology Positive ANA titers ( 1:40) were found in 35 patients (67%), 33 patients (63%) were ASMA-positive ( 1:40), 26 (50%) were both ANA/ASMA-positive, and 10 (19%) were both ANA/ ASMA-negative. None of the patients in seropositive or seronegative groups had staining patterns suggestive for presence of anti-lkm-1 antibody by using IIF testing on a mouse stomachkidney substrate. Treatment Regimens At the time of diagnosis, patients were treated with prednisone either alone (9, 17%) or in combination with azathioprine (42, 79%). One patient was treated with hydroxychloroquine for underlying lupus, which led to improvement of liver function. The patients with autoantibodies were similar to the patients without autoantibodies with respect to initial treatment regimen used (Table 1). Because no preset protocol is followed at our institution, drug doses used at initiation of treatment varied widely among patients and ranged from 10 to 60 mg for prednisone and 50 to 100 mg for azathioprine. Treatment regimen and dosage used depended on treating physician s preference. The hepatology practice at our institution is run by 3 board-certified hepatologists. The number of
3 100 MEHENDIRATTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 7, No. 1 Figure 1. Degree of liver injury on histology was defined by 8 individual categories including plasma cells, portal inflammation, and piecemeal necrosis (A), lobular inflammatory activity (B), centrilobular necrosis (C), and fibrosis (D). patients treated by each individual hepatologist was similar between the seronegative and seropositive groups. Response to Therapy Four (10%) patients in the seropositive group had suboptimal responses to initial treatment, requiring addition of immunosuppressants to treatment regimen (2 treated with mycophenolate mofetil and 2 treated with tacrolimus). One patient (10%) in the seronegative group had worsening clinical and laboratory features requiring orthotopic liver transplantation. There was no statistically significant difference between the mean serum ALT and AST levels at diagnosis and at 1, 6, and 12 months after treatment between the seropositive and the seronegative groups (Table 1). Histologic Data The degree of lobular inflammatory activity was slightly higher in the seronegative group versus the seropositive group (mean score, 1.3 vs 0.95), but the results were not statistically significant (Table 2). Both groups had a similar degree of portal inflammation (1.3 vs 1.5), piecemeal necrosis (0.9 vs 1.2), and plasma cells (1.21 vs 0.9). Centrilobular necrosis was found in liver biopsy specimens of 2 (4%) seropositive patients and in no seronegative patients. Overall, 6 patients had cirrhosis at the time of diagnosis (5 patients with autoantibodies vs 1 patient without autoantibodies). However, the fibrosis stage was similar in patients with or without autoantibodies (1.6 vs 1.4). The extent of biliary changes such as bile duct proliferation (mean score, 0.5 vs 0.6), pericholangitis (0.36 vs 0.6), and cholestasis (0.31 vs 0.7) was comparable between seronegative and seropositive groups. However, changes in biliary architecture were not sufficiently prominent to raise doubt about the diagnosis of AIH. None of the biopsy specimens examined showed atypical features (such as steatosis, iron overload, viral features, or inclusions) to suggest an alternative diagnosis. Discussion The diagnosis of AIH incorporates a set of clinical, serologic, and histologic features that are not specific to the
4 January 2009 SEROLOGY IN AUTOIMMUNE HEPATITIS 101 Table 1. Patient Characteristics in Seropositive and Seronegative AIH Seropositive (n 42) Seronegative (n 10) P value Mean age 52 y 58 y.212 Female sex 35 (83%) 6 (60%).101 Treatment Prednisone alone 7 (16%) 2 (20%).322 Prednisone azathioprine 34 (79%) 8 (80%).367 Other 1 (2%) Mean ALT At diagnosis mo mo mo Mean AST At diagnosis mo mo mo Alkaline phosphatase at diagnosis disease. The diagnosis of AIH in patients who present without serum autoantibodies can be difficult, but it might be made on the basis of a combination of hepatic pattern of serum biochemical abnormalities, marked hypergammaglobulinemia with selective elevation of serum IgG, typical histologic findings, immunogenetic background, and a careful exclusion of other possible causes of liver diseases. 2 The proposed scoring system does not preclude the diagnosis of AIH in these patients, but there is limited literature to date explaining the natural progression of disease and response to conventional treatment in this cohort. Thus, our retrospective study aimed to determine whether the presence or absence of autoantibodies had any correlation or prognostic significance with regard to presentation, disease severity, or treatment response. We found that the presence or absence of autoantibodies did not correlate with the clinical or histologic severity of AIH at diagnosis. Furthermore, there was no correlation between antibody status and response to immunosuppressive therapy. Nineteen percent of patients diagnosed with AIH at our university practice were seronegative for conventional markers of AIH. There was no statistically significant difference between the degree of laboratory and histologic manifestations of hepatocellular inflammation between the seronegative cohort and their seropositive counterparts. ANAs and ASMAs are the most common markers for AIH, but about 20% 30% of AIH patients present without significant titers ( 1:40) of these autoantibodies. There is little evidence that autoantibodies play a part in the pathogenesis of AIH, 9 and titers correlate poorly with disease severity, degree of liver injury, and response to treatment. 8 Titers of ANA and ASMA contribute in calculating the IAIHG diagnostic score for patients with a probable or definite diagnosis of AIH. 2 A score of 1, 2, and 3 is assigned to autoantibody titers of 1:40, 1:80, and 1:80, respectively. A cut-off titer of 1:40 was used to define seropositivity in our study. Similar cutoff has been used by Feld et al 10 while studying the effects of symptoms on the natural history of AIH. They concluded that asymptomatic patients with AIH have a favorable prognosis and might not require immunosuppression. Although both groups had similar proportion of seropositive patients, no correlation was made between autoantibody status or titers and treatment response. In our study 6 patients in the seropositive group had antibody titer of 1:40. These patients did not differ from patients with higher titers ( 1:80) in terms of clinical presentation or response to immunosuppression. IIF was used to test for routine antibodies associated with AIH. A consensus statement in 2004 from the Committee for Autoimmune Serology of the IAIHG provided guidelines on how to test for autoantibodies relevant to AIH and concluded that IIF on fresh sections of multi-organ (liver, kidney, stomach) from rodents (usually rat) should be the first-line screening. 11 Problems associated with the IIF technique include the limited availability and variable quality of the tissue substrate, time-consuming technique, and intraoperator variability requiring highly trained and experienced personnel. This has given way to newer, less time-consuming, and easy to perform automated enzyme-linked immunosorbent assays (ELISAs). Either technique has its pros and cons and gives answers to different questions, such that results are not directly comparable Most liver-related autoantibodies can be detected by IIF when using a triple rodent tissue. HEp-2 cells can help to differentiate ANA patterns, and ethanol-fixed neutrophils can be used for the detection of ANCAs. In contrast, ELISAs give answers for (usually) preselected individual autoantibody specificities. Although the analytical sensitivity of ELISAs is satisfactory, their specificity varies according to the manufacturer, 14 whereas such problems are rather infrequent by IIF testing based on a triple rodent tissue substrate. 15 At the present time, ELISAs should be used to complement but not replace IIF. 16 Histologic features of AIH variably include portal and lobular lymphoplasmacytic necroinflammatory infiltrates, piecemeal necrosis, and bridging necrosis. Complex numeric systems have been proposed for grading and staging of chronic hepatitis, with the intent that these could be used in the statistical analysis in clinical trials. 17 Although there is no gold standard grading and staging system for AIH, the most widely accepted scoring system is the Histological Activity Index, either in its original form, Knodell score, 18 or the modified form, Ishak score. 19 The histologic scoring system used in the current study has been prepared by the authors along the lines of the modified Histological Activity Index and maintains a range of numbers without any missing numbers. Few additional criteria (such as bile duct proliferation, pericholangitis) have been in- Table 2. Histologic Features at Diagnosis Seropositive Seronegative P value Portal inflammation Lobular inflammatory activity Plasma cells Piecemeal necrosis Centrilobular necrosis 4/43 (10%) 0/ Bile duct proliferation Pericholangitis Cholestasis Fibrosis Cirrhosis 5/42 (12%) 1/10 (10%).076
5 102 MEHENDIRATTA ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 7, No. 1 corporated to generate biologically plausible and clinically useful information. Since the early 1990s, various authors have proposed an underlying autoimmune mechanism on patients with chronic hepatitis without significant titers of conventional serum autoantibodies. Johnson et al 20 reported a case series of 12 patients who presented with histologically florid chronic active hepatitis but without significant titers of conventional serum autoantibodies. Clinical and histologic remission was achieved in all cases within 8 months of immunosuppressive therapy. Six patients subsequently relapsed during or after withdrawal of immunosuppression. Czaja et al 21,22 and Kaymakoglu et al 23 studied the clinical features, genetic phenotype, and corticosteroid responsiveness in patients with severe cryptogenic chronic hepatitis and found no difference when compared with AIH patients. Thiele et al 24 studied the effect of corticosteroid-containing therapy in patients with non-b chronic hepatitis and varying anti hepatitis C virus status. Neither the presence nor the relative titers of conventional autoantibodies were significantly associated with steroid responsiveness in patients with chronic hepatitis in this study. More recently, Gassert et al 25 described the criteria for diagnosis of seronegative AIH in 6 patients earlier classified as having cryptogenic chronic hepatitis. The clinical and histologic features and response to corticosteroids in these 6 patients were similar to those of 22 patients with conventional type I AIH. Czaja 8 studied 107 patients with seropositive AIH and followed them for months for response to immunosuppression. Eighty-one (76%) patients lost either one or both autoantibodies (ANA, ASMA) after initial treatment. Disappearance of autoantibodies was associated with lower serum aminotransferase, bilirubin, -globulin, and IgG levels. Interface hepatitis, bridging or lobular necrosis, and active cirrhosis were more commonly associated with ANA and/or ASMA seropositivity. However, in our study there was a slightly higher degree of lobular inflammation, portal inflammation, and piecemeal necrosis, which was not statistically significant. Furthermore, the aminotransferase levels at diagnosis were slightly higher in the seronegative group than in the seropositive group. It is possible that a delay in the initial diagnosis associated with seronegativity accounted for a slightly greater degree of disease severity at presentation. In the study by Czaja, 8 patients were followed from seropositivity to seronegativity after treatment, and changes in clinical and histologic characteristics were studied. Our study assessed the clinicopathologic features of patients with seronegative AIH when compared with patients with seropositive AIH before initiation of immunosuppression. Hence, our findings add a new dimension to the understanding of AIH, specifically as regards to the clinical and histologic characteristics of seronegative AIH. Ten percent of patients within both seropositive and seronegative groups showed suboptimal response to initial immunosuppressive therapy. This finding is similar to a recent study by Montano-Loza et al, 26 who reported a failure rate of 7% (14 of 214) in patients with type 1 AIH treated with conventional corticosteroid treatment. 27 Patients who failed therapy in this study 27 were younger, had higher serum bilirubin levels, and presented more acutely. In our study, we did not find any significant difference between responders and nonresponders. When patients were followed for 1 year after the institution of immunosuppression, there was no significant difference between the aminotransferase levels at 1, 6, and 12 months after treatment between seronegative and seropositive groups. Limitations of our study include smaller sample size when compared with earlier studies. 8,26 Because of the retrospective nature of our study, certain information like IgG level was not available on all patients. We have not done subgroup analysis on the basis of autoantibody titers. However, this study compares the clinical and histologic characteristics of seronegative and seropositive AIH before initiation of therapy with AIH, adding a new dimension to our understanding of AIH. In conclusion, our data suggest that antibody status should not be used to predict AIH activity or outcome. Patients who meet the diagnosis of AIH on the basis of the revised scoring system of IAIHG should be treated with immunosuppression, irrespective of antibody status. References 1. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18: Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31: Czaja AJ, Carpenter HA. Validation of scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41: Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6: Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003;37: Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104: Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125: Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30: Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354: Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42: Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41: Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities: II potential for quantitation of antibody content. J Rheumatol 2002;29: Fritzler MJ, Wiik A, Tan EM, et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities: III comparative performance characteristics of academic and manufacturers laboratories. J Rheumatol 2003;30: Fritzler MJ, Wiik A, Fritzler ML, et al. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003;5: Rondeel JM, van Gelder W, van der Leeden H, et al. Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked immunosorbent assay or both? Ann Clin Biochem 1999;36: Bogdanos DP, Invernizzi P, Mackay R, et al. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008;14: Goodman ZD. Grading and staging for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007;47:
6 January 2009 SEROLOGY IN AUTOIMMUNE HEPATITIS Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1: Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: Johnson PJ, McFarlene IG, McFarlene BM, et al Auto-immune features in patients with idiopathic chronic active hepatitis who are seronegative for convenional auto-antibodies. J Gastroenterol Hepatol 1990:5: Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990;65: Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104: Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis. J Hepatol 1998;28: Thiele D, DuCharme L, Cunningham MR, et al. Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and negative patients. Am J Gastroenterol 1996;91: Gassert DJ, Garcia H, Tanaka K, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence of seronegative autoimmune hepatitis. Dig Dis Sci 2007;52: Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage live disease. Hepatology 2007;46: Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36: Address requests for reprints to: Steven K. Herrine, MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University, 132 S 10th Street, #450, Philadelphia, Pennsylvania steven. herrine@jefferson.edu; fax: (215) The authors disclose no conflicts.
Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 131-136, 2014 Evaluation of the revised versus the simplified scoring system in patients with autoimmune hepatitis YI LI, MILIN PENG and GUOZHONG GONG Institute
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationIn 1993, the International Autoimmune Hepatitis Group
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:417 421 Validation and Modification of Simplified Diagnostic Criteria for Autoimmune Hepatitis in Children ELIZABETH MILETI,* PHILIP ROSENTHAL,*, and MARION
More informationAutoimmune hepatitis
Autoimmune hepatitis: Autoimmune hepatitis a spectrum within a spectrum Alastair Burt Professor of Pathology and Dean of Clinical Medicine Newcastle University Spectrum of autoimmune liver disease Autoimmune
More informationCLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2011;140:1472 1480 Comparability of Probable and Definite Autoimmune Hepatitis by International Diagnostic Scoring Criteria ALBERT J. CZAJA Division of Gastroenterology and Hepatology,
More informationAutoimmune Hepatitis: Histopathology
REVIEW Autoimmune Hepatitis: Histopathology Stephen A. Geller M.D.*, Autoimmune hepatitis (AIH), a chronic hepatic necroinflammatory disorder, occurs mostly in women. AIH is characterized by prominent
More informationAutoimmune Liver Diseases
2nd Pannonia Congress of pathology Hepato-biliary pathology Autoimmune Liver Diseases Vera Ferlan Marolt Institute of pathology, Medical faculty, University of Ljubljana Slovenia Siofok, Hungary, May 2012
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationClinical characteristics and response to therapy of autoimmune hepatitis in an urban Latino population
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases BRIEF REPORT Clinical characteristics and response to therapy of autoimmune hepatitis
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationA Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1036 1040 A Single Center Review of the Use of Mycophenolate Mofetil in the Treatment of Autoimmune Hepatitis JONATHAN T. HLIVKO, MITCHELL L. SHIFFMAN, R.
More informationSerologic Markers CONVENTIONAL ANTIBODIES ANTIBODIES UNCONVENTIONAL. AIH Type I
Autoimmune Hepatitis By Thomas Frazier Objective What we need to know about AIH Diagnosis Treatment Difficulties in both Liver transplantation concerns AASLD Guidelines: Hepatology. 2010 Jun;51(6):2193-213.
More informationA Case of Autoimmune Hepatitis with Antimitochondrial Antibody and No Detectable Antinuclear Antibody
FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF St. Marianna Med. J. Case Report Vol. 32, pp. 33 38, 2004 FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF A Case
More informationDiagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems
Jikeikai Med J 2011 ; 58 : 89-93 Review Diagnostic Criteria for Autoimmune Hepatitis : Historical Review and Present Problems Mikio Zeniya and Hiroki Takahashi Department of Gastroenterology and Hepatology,
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationNews. Laboratory. CHANGES IN CARDIAC TROPONIN I REPORTING Gene Shaw, MD, Annu Khajuria, PhD. Inside This Issue
Laboratory News Inside This Issue CHANGES IN CARDIAC TROPONIN I REPORTING...1 FOUR NEW SEROLOGY TESTS FOR AUTOIMMUNE LIVER DISEASES...3 INSULIN LIKE GROWTH FACTOR-1 (IGF-1) METHOD CHANGES...6 CHANGES IN
More informationAutoimmune Hepatitis: Clinical Overview and Pathological Findings
6 Jan 2018 Vol 11 No.1 North American Journal of Medicine and Science Review Autoimmune Hepatitis: Clinical Overview and Pathological Findings Simpal Gill, MD* Pathology Laboratory services, Houston Medical
More informationNovel Therapies in Autoimmune Hepatitis
Novel Therapies in Autoimmune Hepatitis Paul W. Rassam,MD Ass. Clinical Professor of Medicine Div. of Gastroenterology and Hepatology St George Hospital University Medical Center University of Balamand
More informationComparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis
Elmer Original Article ress Comparing Efficacy Between Regimens in the Initial Treatment of Autoimmune Hepatitis Chijioke Enweluzo a, b, Fahad Aziz a, Amit Mori a Abstract Background: Autoimmune hepatitis
More informationDiagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationDiagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 177-203 Review Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions Albert J. Czaja Division of Gastroenterology and Hepatology,
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationDomenico ALVARO, MD Sapienza, University of Rome, Italy. Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015.
Epatite autoimmune e sindrome da "overlap Domenico ALVARO, MD Sapienza, University of Rome, Italy Congresso Nazionale della Società Italiana di GastroReumatologia, Roma, 25 Giugno 2015. AUTOIMMUNE HEPATITIS
More informationHwajeong Lee, MD, Robert T. Stapp, DO, Adrian H. Ormsby, MD, and Veena V. Shah, MD
Anatomic Pathology / Overlap Syndrome The Usefulness of IgG and IgM Immunostaining of Periportal Inflammatory Cells (Plasma Cells and Lymphocytes) for the Distinction of Autoimmune Hepatitis and Primary
More informationChronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths
Chronic Biliary Disease Dr Susan Davies & Dr Bill Griffiths Chronic Biliary Disease Terminology is confusing with pathologists and hepatologists using the same language BUT with different meanings. Chronic
More informationAutoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018
Autoimmune Hepatitis Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern November 14th, 2018 AIH - Definition Manns MP J Hepatol 2015, vol 62, P 100-111 AIH - Definition Autoimmune hepatitis (AIH) is
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationBasic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationUpdate on Autoimmune Liver Disease. Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC
Update on Autoimmune Liver Disease Role of Liver Biopsy in Autoimmune Hepatitis, PBC and PSC Stefan Hübscher, School of Cancer Sciences, University of Birmingham Dept of Cellular Pathology, Queen Elizabeth
More informationAutoimmune hepatitis (AIH) is a rare disease, yet it. Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:625 631 Fulminant Hepatic Failure as the Initial Presentation of Acute Autoimmune Hepatitis WILLIAM R. KESSLER,* OSCAR W. CUMMINGS, GEORGE ECKERT, NAGA CHALASANI,*
More informationLong-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center
GASTROENTEROLOGY 2011;140:1980 1989 Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center BARBARA HOEROLDT, ELAINE MCFARLANE,* ASHA DUBE, PANDURANGAN BASUMANI, MOHAMMED
More informationGuideline Summary NGC-8005
NGC banner Guideline Summary NGC-8005 Guideline Title Diagnosis and management of autoimmune hepatitis. Bibliographic Source(s) Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling
More informationBritish Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis
1 Liver Unit, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK 2 Institute of Liver Studies, King s College Hospital NHS Foundation Trust, London, UK Correspondence to Dr Dermot Gleeson, P
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationbudesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd
budesonide, 3mg, gastro-resistant capsules (Budenofalk ) SMC No. (1043/15) Dr Falk Pharma UK Ltd 10 April 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationCase #1. Digital Slides 11/6/ year old woman presented with abnormal liver function tests. Liver Biopsy to r/o autoimmune hepatitis
45 year old woman presented with abnormal liver function tests Liver Biopsy to r/o autoimmune hepatitis Further down. ANA 1: 160; ASMA 1:80 ANA 1: 160; ASMA 1:80 IgG = 14.5 g/l (upper normal range: 16)
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationThere is no specific diagnostic test for autoimmune
Long-Term Follow-Up of Antimitochondrial Antibody Positive Autoimmune Hepatitis Conor O Brien, 1 Supriya Joshi, 1 Jordan J. Feld, 2 Maha Guindi, 3 Hans P. Dienes, 4 and E. Jenny Heathcote 1 Antimitochondrial
More informationTwo Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults
CASE REPORT Two Cases of Primary Sclerosing Cholangitis Overlapping with Autoimmune Hepatitis in Adults Go Igarashi 1, Tetsu Endo 1, Kenichiro Mikami 1, Naoya Sawada 1,RyuSatake 1, Rie Ohta 1, Juichi Sakamoto
More informationSlide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.
Many of the histologic images and the tables are from MacSween s Pathology of the Liver (5 th Edition). Other images were used from an online source called PathPedia.com. A few images from other sources
More informationAutoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response
0021-7557/02/78-04/309 Jornal de Pediatria Copyright 2002 by Sociedade Brasileira de Pediatria Jornal de Pediatria - Vol. 78, Nº4, 2002 309 ORIGINAL ARTICLE Autoimmune hepatitis in children and adolescents:
More informationHepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:
Hepatitis Dr. Mohamed. A. Mahdi Mob: 0123002800 5/2/2019 Hepatitis Hepatitis means the inflammation of the liver. May cause by viruses or bacteria, parasites, radiation, drugs, chemical and toxins (alcohol).
More informationMinocycline as a Cause of Drug-Induced Autoimmune Hepatitis Report of Four Cases and Comparison With Autoimmune Hepatitis
Anatomic Pathology / MINOCYCLINE-INDUCED AUTOIMMUNE HEPATITIS Minocycline as a Cause of Drug-Induced Autoimmune Hepatitis Report of Four Cases and Comparison With Autoimmune Hepatitis Neal S. Goldstein,
More informationAssessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY
Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY Disclosures Nothing to Disclose Assessing the patient with a new diagnosis of Hepatitis
More informationHistopathology of De Novo Autoimmune Hepatitis
LIVER TRANSPLANTATION 18:811-818, 2012 ORIGINAL ARTICLE Histopathology of De Novo Autoimmune Hepatitis Ananya Pongpaibul, 1 Robert S. Venick, 2 Sue V. McDiarmid, 3 and Charles R. Lassman 4 1 Department
More informationImprovement of Rheumatoid Arthritis and Autoimmune Hepatitis in a Patient Treated with the Tumor Necrosis Factor Inhibitor, Etanercept
CASE REPORT Improvement of Rheumatoid Arthritis and Autoimmune Hepatitis in a Patient Treated with the Tumor Necrosis Factor Inhibitor, Etanercept Kunihiko Umekita 1, Shunichi Miyauchi 1, Shiro Ueno 1,
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationAldo Torre., 2011; 10 (1): 28-32
28 ORIGINAL ARTICLE January-March, Vol. 10 No.1, 2011: 28-32 Does HLA-DR7 differentiate the overlap syndrome of auto-immune hepatitis-primary biliary cirrhosis (AIH-PBC) from those with auto-immune hepatitis
More informationClinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients
Hepat Mon. 2012;12(2):92-99. DOI: 10.5812/hepatmon.808 KOWSAR www.hepatmon.com Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients 1,2 Zinab Malekzadeh, Sepideh Haghazali
More informationDiseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:
Diseases of liver Dr. Mohamed. A. Mahdi Mob: 0123002800 4/2/2019 Cirrhosis Cirrhosis is a complication of many liver disease. Permanent scarring of the liver. A late-stage liver disease. The inflammation
More informationAcute and Chronic Hepatitis John Hart, M.D. University of Chicago Medical Center
Acute and Chronic Hepatitis John Hart, M.D. University of Chicago Medical Center Acute Hepatitis Clinical Features Classically acute hepatitis is defined clinically as a significant (at least 2X elevation
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationPatologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases
Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases Harrison s Principles of Internal Medicine 18-19 Ed. 2012 e seguenti Chronic hepatitis classification by cause
More informationImmunopathogenesis: Insights for Current and Future Therapies
REVIEW Immunopathogenesis: Insights for Current and Future Therapies John M. Vierling, M.D., F.A.C.P. Autoimmune hepatitis (AIH) is a chronic, progressive, necroinflammatory disease caused by loss of tolerance
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationAASLD PRACTICE GUIDELINES. Diagnosis and Management of Autoimmune Hepatitis. 1. Preamble. 2. Introduction
AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis Michael P. Manns, 1 Albert J. Czaja, 2 James D. Gorham, 3 Edward L. Krawitt, 4 Giorgina Mieli-Vergani, 5 Diego Vergani, 6 and
More informationPITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017
CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017 I HAVE NOTHING TO DISCLOSE Linda Ferrell PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES Linda Ferrell, MD, UCSF THE PROBLEM
More informationDifficult treatment decisions in autoimmune hepatitis
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v16.i8.934 World J Gastroenterol 2010 February 28; 16(8): 934-947 ISSN 1007-9327 (print) 2010 Baishideng. All rights
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationViral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel. Basel,
Viral Hepatitis (I) Luigi Terracciano Department of Pathology University Hospital Basel Basel, 19. 04. 2016 Definition Hepatitis means inflammation of the liver characterized by a variable combination
More informationBSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D
BSG/ACP annual course Royal College of Pathologists Infections and Inflammations of the Hepato-Biliary System Hepatitis B and D Amar Paul Dhillon Royal Free & University College Medical School Thurs 10
More informationAutoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management
Drugs Aging https://doi.org/10.1007/s40266-018-0556-0 THERAPY IN PRACTICE Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management Syed Rizvi 1 Samer Gawrieh 2 Ó Springer International
More informationLong-term Treatment Outcomes for Autoimmune Hepatitis in Korea
J Korean Med Sci 21; 25: 54-6 ISSN 111-8934 DOI: 1.3346/jkms.21.25.1.54 Long-term Treatment Outcomes for Autoimmune Hepatitis in Korea Immunosuppressive therapy can improve clinical, biochemical and histological
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationWhat s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis
What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis A combination of improved surgical techniques, donor organ preservation, selection
More informationS ince the discovery of hepatitis C, there have been several
402 ORIGINAL ARTICLE Steatosis and fibrosis in patients with chronic hepatitis C J Wyatt, H Baker, P Prasad, Y Y Gong, C Millson... See end of article for authors affiliations... Correspondence to: Dr
More information21/07/2017. Update on Autoimmune Biliary Disease. Changing Role of Liver Biopsy in PBC and PSC. Primary Biliary Cirrhosis Cholangitis
Primary Biliary Cirrhosis Cholangitis Update on Autoimmune Biliary Disease Changing Change in Nomenclature for PBC : From Cirrhosis to Cholangitis (EASL Panel, Beuers et al J Hepatol Nov 2015, Gut Nov
More informationFeatures of Autoimmune Hepatitis in Egyptian Children
Med. J. Cairo Univ., Vol. 78, No. 1, March: 107-112, 2010 www.medicaljournalofcairouniversity.com Features of Autoimmune Hepatitis in Egyptian Children NEHAL EL-KOOFY, M.D.; MONA FAHMY, M.D.*; MONA AZIZ,
More informationValue of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1355 1360 Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease PIOTR MILKIEWICZ,*, HAYMAN BUWANESWARAN,* CATALINA
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationFibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD
Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes Carla Venturi Monteagudo MD, PhD THE NORMAL LIVER ARCHITECTURE Parenchymal Cells -Hepatocytes -Cholangiocytes
More informationThe International Autoimmune Hepatitis Group
Diagnostic Value and Utility of the Simplified International Autoimmune Hepatitis Group (IAIHG) Criteria in Acute and Chronic Liver Disease Andrew D. Yeoman, Rachel H. Westbrook, Thawab Al-Chalabi, Ivana
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationIntroduction. Kaoru Omori 1 Masahiro Kan 1. Kanako Yoshida
Clin J Gastroenterol (2016) 9:312 318 DOI 10.1007/s28-016-0676-1 CASE REPORT Familial occurrence of autoimmune liver disease with overlapping features of primary biliary cholangitis and autoimmune hepatitis
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationLiver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationCase Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation
108 Diagnostic Problems in Hepatology Case Report of Successful Treatment of Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin after Liver Transplantation Brian Kim, MD 1 Anshu Trivedi, MD
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationBritish Liver Transplant Group Pathology meeting September Leeds cases
British Liver Transplant Group Pathology meeting September 2014 Leeds cases Leeds Case 1 Male 61 years Liver transplant for HCV cirrhosis with HCC in January 2014. Now raised ALT and bilirubin,? acute
More informationType 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the acute type
Q J Med 2004; 97:407 412 doi:10.1093/qjmed/hch072 Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the acute type R. FERRARI 1, G. PAPPAS 1, D. AGOSTINELLI 1,
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationNot All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases
Not All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases Prevalence of Chronic Liver Disorders in the United States Nonalcoholic Fatty Liver Disorder
More informationOriginal Article Autoimmune hepatitis in patients with primary Sjögren s syndrome: a series of two-hundred and two patients
Int J Clin Exp Pathol 2010;3(6):582-586 www.ijcep.com /IJCEP1004002 Original Article Autoimmune hepatitis in patients with primary Sjögren s syndrome: a series of two-hundred and two patients Julie K.
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationHellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis
SPECIAL ARTICLE Annals of Gastroenterology (2019) 32, 1-24 Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis George N. Dalekos a,b, John Koskinas c, George
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationSHORT TITLE: Predictors of response to autoimmune hepatitis treatment.
TITLE PAGE TITLE: Liver dysfunction and fibrosis as predictors of biochemical response to autoimmune hepatitis treatment. SHORT TITLE: Predictors of response to autoimmune hepatitis treatment. AUTHORS:
More informationT he diagnosis of autoimmune hepatitis (AIH) is based on a
259 LIVER DISEASE Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics M Baeres, J Herkel, A J Czaja, I Wies, S Kanzler,
More information